Linvoseltamab + Lenalidomide for Multiple Myeloma

Overseen By Dickran Kazandjian, MD

Age: Any Age

Sex: Any

Trial Phase: Phase 2

Sponsor: Dickran Kazandjian, MD

Must be taking: Lenalidomide

Must not be taking: Investigational agents

Disqualifiers: HIV, Hepatitis B, Hepatitis C, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 24 months

32 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether combining lenalidomide with linvoseltamab, a new potential drug, can better manage multiple myeloma, a type of blood cancer. Researchers aim to determine if this combination can eliminate leftover cancer cells, control the disease longer, and improve treatment responses. The trial targets patients who have received lenalidomide for up to a year, with some showing minor signs of relapse. Those diagnosed with multiple myeloma and on lenalidomide maintenance therapy might find this trial suitable. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are on other investigational agents or have contraindications to certain medications used in the study. It's best to discuss your specific medications with the study team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that combining linvoseltamab with other treatments is safe for patients with multiple myeloma, a type of blood cancer. For instance, when used with carfilzomib, linvoseltamab achieved high success rates and was well tolerated by patients. This indicates that linvoseltamab might be a safe option in combination with other treatments.

Lenalidomide, another drug in this trial, is already known for its safety. It is frequently used to treat multiple myeloma and helps improve patient outcomes. Studies have demonstrated that using linvoseltamab and lenalidomide together is safe.

Although linvoseltamab is still under testing, its use in other combinations suggests it is generally well-tolerated. The advanced stage of this trial indicates that earlier tests have already shown it to be reasonably safe. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Linvoseltamab is unique because it offers a novel approach to treating multiple myeloma by targeting a specific protein on cancer cells known as BCMA (B-cell maturation antigen). Unlike traditional therapies that may not specifically target this protein, Linvoseltamab directly engages BCMA, potentially leading to more efficient elimination of cancer cells. Researchers are excited about this treatment because it could enhance the effectiveness of existing therapies like lenalidomide, especially in patients who have relapsed or have limited response to standard treatments. By combining Linvoseltamab with lenalidomide, there's hope for improving outcomes and extending the duration of response in patients with multiple myeloma.

What evidence suggests that linvoseltamab combined with lenalidomide could be effective for multiple myeloma?

In this trial, participants will receive a combination of linvoseltamab and lenalidomide to treat multiple myeloma, a type of blood cancer. Research has shown that using linvoseltamab with lenalidomide may be effective, with about 91.9% of patients responding positively, significantly reducing cancer cells. Participants in Cohort 1 will have linvoseltamab added to their ongoing lenalidomide maintenance therapy. Meanwhile, Cohort 2 participants, who have relapsed disease, will also receive the combination treatment. Early results suggest that adding linvoseltamab to lenalidomide is safe and can lead to a strong decrease in cancer signs. Overall, these findings support the potential of this combination to control multiple myeloma. ^{1 2 3 5 6}

Who Is on the Research Team?

Dickran Kazandjian, MD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

This trial is for individuals with newly diagnosed multiple myeloma (NDMM) who are undergoing maintenance therapy. It aims to deepen response to treatment and achieve or maintain minimal residual disease negativity, especially after a relapse.

Inclusion Criteria

Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines

Willing and able to comply with clinic visits and study-related procedures

I have been diagnosed with multiple myeloma for the first time.

Exclusion Criteria

Patients who are receiving any other investigational agents unless deemed not to interfere with the study by the Principal Investigator (PI)

History of allergic reactions attributed to compounds of similar chemical or biologic composition to the experimental agents used in study

Participant plans to father a child while enrolled in this study or within 3 months after the last dose of study treatment

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive linvoseltamab in addition to lenalidomide during maintenance therapy for up to 24 cycles

Up to 24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 2 years

Long-term follow-up

Participants are monitored for progression-free survival and overall survival

Up to 4.5 years

What Are the Treatments Tested in This Trial?

Interventions

• Lenalidomide
• Linvoseltamab

Trial Overview

The study tests the combination of linvoseltamab and lenalidomide during maintenance therapy in NDMM patients. The goal is to eliminate remaining cancer cells, prolong disease control, and extend the duration of treatment response.

How Is the Trial Designed?

Group I: Cohort 2 - Lenalidomide Treatment Group Experimental Treatment 2 Interventions

Participants in this group are currently receiving lenalidomide maintenance therapy but have relapsed disease within 12 months of starting maintenance will have Linvoseltamab added to lenalidomide maintenance and receive treatment with the combination for up to 24 cycles. Total participation duration is up to 4.5 years

Group II: Cohort 1 - Linvoseltamab Treatment Group Experimental Treatment 2 Interventions

Participants in this group are currently receiving lenalidomide maintenance therapy for ≤12 months will have linvoseltamab added to the lenalidomide maintenance therapy and receive treatment with the combination for up to 24 cycles. Total participation duration is up to 4.5 years

Who Is Running the Clinical Trial?

Dickran Kazandjian, MD

Lead Sponsor

Trials

1

Recruited

30+

Regeneron Pharmaceuticals

Industry Sponsor

Trials

690

Recruited

948,000+

Founded

1988

Headquarters

Tarrytown, USA

Known For

Precision medicine

Top Products

Dupixent, EYLEA, Libtayo, Praluent

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School

Published Research Related to This Trial

Lenalidomide, when combined with dexamethasone, is a safe and effective treatment for newly diagnosed multiple myeloma patients who cannot undergo autologous stem cell transplantation, providing rapid disease control.

Long-term use of lenalidomide has led to significant improvements in progression-free survival for patients ineligible for stem cell transplantation and has resulted in deep, durable remissions for those with relapsed or refractory multiple myeloma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An update on the use of lenalidomide for the treatment of multiple myeloma. Zagouri, F., Terpos, E., Kastritis, E., et al.[2018]

A subgroup analysis from two phase III clinical trials demonstrated that combining lenalidomide with dexamethasone is more effective than using dexamethasone alone for patients with relapsed or refractory multiple myeloma who had prior treatment with thalidomide.

This finding suggests that the lenalidomide and dexamethasone combination could be a more beneficial treatment option for these patients, potentially improving their outcomes in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. Meijer, E., Sonneveld, P.[2021]

Lenalidomide combined with dexamethasone has been shown to be effective for treating relapsed/refractory multiple myeloma, and it has received approval from both the FDA and EMA for patients who have undergone at least one prior therapy.

The most common serious side effects include cytopenias and infections, but an expert panel has provided management strategies to minimize these risks, ensuring that patients can receive the full benefits of the treatment without unnecessary dose reductions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Palumbo, A., Dimopoulos, M., San Miguel, J., et al.[2018]

Lenalidomide, when combined with dexamethasone (Len/Dex), significantly improves overall survival in patients with relapsed or refractory multiple myeloma compared to dexamethasone alone, as shown in pivotal phase III trials.

Lenalidomide has a manageable safety profile with minimal neurotoxicity, making it suitable for long-term use, and is also effective as an induction therapy for newly diagnosed multiple myeloma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

How lenalidomide is changing the treatment of patients with multiple myeloma. Dimopoulos, MA., Terpos, E., Niesvizky, R.[2013]

In a phase 3 trial involving 559 patients with relapsed or refractory multiple myeloma who had previously received lenalidomide, the combination of pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared to bortezomib and dexamethasone alone, with a median survival of 11.20 months versus 7.10 months.

While the combination treatment showed better efficacy, it also resulted in higher rates of serious adverse events, particularly neutropenia and infections, indicating that while effective, careful monitoring for side effects is necessary.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson, PG., Oriol, A., Beksac, M., et al.[2020]

Lenalidomide is an effective treatment for patients with relapsed or refractory multiple myeloma, showing promising clinical activity and is approved by the FDA.

Common side effects of lenalidomide include neutropenia, thrombocytopenia, and thromboembolic events, necessitating careful monitoring to prevent serious complications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Tariman, JD.[2018]

Lenalidomide has shown significant efficacy in improving survival rates for patients with relapsed and refractory myeloma, especially when used alongside other treatments like bortezomib and thalidomide.

While lenalidomide is effective, it is associated with common side effects such as fatigue and thrombocytopenia, and its combination with other agents can increase the risk of blood clots, highlighting the importance of managing these adverse events for continued treatment success.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lenalidomide for the treatment of relapsed and refractory multiple myeloma. van de Donk, NW., Görgün, G., Groen, RW., et al.[2021]

Lenalidomide is an effective immunomodulatory drug primarily used to treat multiple myeloma, myelodysplastic syndromes, and amyloidosis, but it can cause significant adverse reactions.

The review specifically highlights cutaneous adverse reactions associated with lenalidomide, which include skin eruptions, alongside other serious side effects like myelosuppression and venous thromboembolism.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cutaneous adverse reactions to lenalidomide. Imbesi, S., Allegra, A., Calapai, G., et al.[2018]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06910124

Study Details | NCT06910124 | Linvoseltamab in Addition ...

The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma ...

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S0268960X25000876

Bispecific antibodies in multiple myeloma

Early results show a high response rate of 91.9 % and an manageable safety profile [68]. In transplant-eligible patients, more mature data was ...

3.

targetedonc.com

targetedonc.com/view/deep-responses-and-favorable-safety-with-linvoseltamab-in-hr-smm

Deep Responses and Favorable Safety with ...

That study showed that 2 years of treatment with lenalidomide was able to delay progression to myeloma and also to improve overall survival in ...

4.

onclive.com

onclive.com/view/linvoseltamab-plus-carfilzomib-is-safe-feasible-and-elicits-durable-responses-in-r-r-myeloma

Linvoseltamab Plus Carfilzomib Is Safe, Feasible, and ...

Linvoseltamab and carfilzomib combination showed a 90% overall response rate in relapsed/refractory multiple myeloma patients, with notable ...

5.

withpower.com

withpower.com/trial/phase-2-multiple-myeloma-5-2025-c70dd

Linvoseltamab + Lenalidomide for Multiple Myeloma

Long-term use of lenalidomide has led to significant improvements in progression-free survival for patients ineligible for stem cell transplantation and has ...

6.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7513

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) ...

Results: As of Sep 30, 2024, 18 pts were treated at DL1 (n = 12) or DL1b (n = 6). Median duration of follow-up was 16.9 (DL1) and 7.7 months ( ...